Treatment of polycystic ovary patients undergoing IVF.
Barri
P N
PN
Department of Obstetrics and Gynecology, Institut Universitari Dexeus, Barcelona, Spain.
Coroleu
B
B
Martinez
F
F
Traver
J M
JM
Veiga
A
A
Calderon
G
G
D000022:Abortion, Spontaneous / Q000517:prevention & control*; D000418:Albumins / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D002064:Buserelin / Q000627:therapeutic use; D004958:Estradiol / Q000378:metabolism; D005260:Female; D005307:Fertilization in Vitro / Q000379:methods* / Q000706:statistics & numerical data; D005640:Follicle Stimulating Hormone / Q000627:therapeutic use; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives / Q000627:therapeutic use; D013006:Growth Hormone / Q000627:therapeutic use; D006801:Humans; D007986:Luteinizing Hormone / Q000378:metabolism; D008596:Menotropins / Q000627:therapeutic use; D009865:Oocytes / Q000187:drug effects / Q000502:physiology*; D016471:Ovarian Hyperstimulation Syndrome / Q000378:metabolism* / Q000517:prevention & control; D011085:Polycystic Ovary Syndrome / Q000378:metabolism / Q000628:therapy*; D011247:Pregnancy
D000418:Albumins; D018931:Antineoplastic Agents, Hormonal; D007987:Gonadotropin-Releasing Hormone; D004958:Estradiol; D008596:Menotropins; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D013006:Growth Hormone; D002064:Buserelin